Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

News in brief

Parexel CEO sells $2.4M in stock


Parexel CEO Josef Von Rickenbach unloaded 50,000 shares of stock last Friday. 

The stock was worth $2.485M, according to SEC documents . Von Rickenbach still owns about $30M in stock, according to news reports .

The sell-off comes as Parexel recently exceeded expectations with its second quarter results.

Analysts at Barclays raised their price target on Parexel shares from $48.00 to $52.00 in a research note from last week, while analysts at ISI Group upgraded shares of the company’s stock from a “buy” rating to a “strong-buy” rating in a research note to investors on Wednesday, January 22nd.

And analysts at Thomson Reuters/Verus downgraded shares of Parexel. One research analyst has rated the stock with a sell rating, seven have given it a hold rating, five have offered a buy rating and two have said the stock deserves a strong buy rating, according to reports. 

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

On demand Supplier Webinars

A brief history of bioavailability
William Reed Business Media
Bioavailability market dynamics
William Reed Business Media
All supplier webinars